The author deals with new findings in research and clinical application of atypical neuroleptic drugs, MAO inhibitors, in particular and second generation, and non-diazepine anxiolytics, in particular serotonergic ones. He summarizes the possibilities of psychopharmacotherapy of clinical units which will be included in the 10th revision of the International statistical classification of diseases, injuries and causes of death, i.e. panic anxiety, obsessive compulsive disorder, agoraphobia with panic attacks and generalized disorder of anxiety.